ULTRAGENYX PHARMACEUTICAL INC. Other Income and Expense
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Other Income and Expense of $4.49 million for the 3-month period ending 2017-09-30, per its 10-Q filed 2017-11-03.
Discontinued › Income Statement › Other Income
us-gaap:NonoperatingIncomeExpense · last filed 2017-11-03
- ULTRAGENYX PHARMACEUTICAL INC. nonoperating income (expense) for the quarter ending 2017-09-30 was $4.49M, a 412.56% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. nonoperating income (expense) for the quarter ending 2017-06-30 was $5.56M, a 392.39% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. nonoperating income (expense) for the quarter ending 2017-03-31 was $1.66M, a 92.37% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. nonoperating income (expense) for the quarter ending 2016-12-31 was -$703.00K, a 174.95% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. nonoperating income (expense) for fiscal 2016 was $2.17M, a 2.26% increase from fiscal 2015.
- ULTRAGENYX PHARMACEUTICAL INC. nonoperating income (expense) for fiscal 2015 was $2.12M.
- ULTRAGENYX PHARMACEUTICAL INC. nonoperating income (expense) for fiscal 2014 was -$3.02M.
- ULTRAGENYX PHARMACEUTICAL INC. nonoperating income (expense) for fiscal 2013 was -$2.79M.
| Period end | Nonoperating Income (Expense) 3 month | Nonoperating Income (Expense) 6 month | Nonoperating Income (Expense) 9 month | Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2017-09-30 | $4.49M 10-Q · filed 2017-11-03 | $10.05M derived: sum of 2 quarters · filed 2017-11-03 | $11.72M 10-Q · filed 2017-11-03 | $11.02M derived: sum of 4 quarters · filed 2017-11-03 |
| 2017-06-30 | $5.56M 10-Q · filed 2017-07-28 | $7.23M 10-Q · filed 2017-07-28 | $6.53M derived: sum of 3 quarters · filed 2017-07-28 | $7.40M derived: sum of 4 quarters · filed 2017-11-03 |
| 2017-03-31 | $1.66M 10-Q · filed 2017-05-05 | $961.00K derived: sum of 2 quarters · filed 2017-05-05 | $1.84M derived: sum of 3 quarters · filed 2017-11-03 | $2.97M derived: sum of 4 quarters · filed 2017-11-03 |
| 2016-12-31 | -$703.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $173.00K derived: sum of 2 quarters · filed 2017-11-03 | $1.30M derived: sum of 3 quarters · filed 2017-11-03 | $2.17M 10-K · filed 2017-02-17 |
| 2016-09-30 | $876.00K 10-Q · filed 2017-11-03 | $2.01M derived: sum of 2 quarters · filed 2017-11-03 | $2.87M 10-Q · filed 2017-11-03 | $3.81M derived: sum of 4 quarters · filed 2017-11-03 |
| 2016-06-30 | $1.13M 10-Q · filed 2017-07-28 | $2.00M 10-Q · filed 2017-07-28 | $2.93M derived: sum of 3 quarters · filed 2017-07-28 | $3.64M derived: sum of 4 quarters · filed 2017-07-28 |
| 2016-03-31 | $865.00K 10-Q · filed 2017-05-05 | $1.80M derived: sum of 2 quarters · filed 2017-05-05 | $2.51M derived: sum of 3 quarters · filed 2017-05-05 | $2.86M derived: sum of 4 quarters · filed 2017-05-05 |
| 2015-12-31 | $938.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $1.64M derived: sum of 2 quarters · filed 2017-02-17 | $2.00M derived: sum of 3 quarters · filed 2017-02-17 | $2.12M 10-K · filed 2017-02-17 |
| 2015-09-30 | $704.00K 10-Q · filed 2016-11-08 | $1.06M derived: sum of 2 quarters · filed 2016-11-08 | $1.18M 10-Q · filed 2016-11-08 | $1.39M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | $355.00K 10-Q · filed 2016-08-09 | $478.00K 10-Q · filed 2016-08-09 | $683.00K derived: sum of 3 quarters · filed 2017-02-17 | $669.00K derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | $123.00K 10-Q · filed 2016-05-10 | $328.00K derived: sum of 2 quarters · filed 2017-02-17 | $314.00K derived: sum of 3 quarters · filed 2017-02-17 | $390.00K derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | $205.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $191.00K derived: sum of 2 quarters · filed 2017-02-17 | $267.00K derived: sum of 3 quarters · filed 2017-02-17 | -$3.02M 10-K · filed 2017-02-17 |
| 2014-09-30 | -$14.00K 10-Q · filed 2015-11-10 | $62.00K derived: sum of 2 quarters · filed 2015-11-10 | -$3.23M 10-Q · filed 2015-11-10 | -$5.02M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-06-30 | $76.00K 10-Q · filed 2015-08-14 | -$3.21M 10-Q · filed 2015-08-14 | -$5.01M derived: sum of 3 quarters · filed 2016-02-26 | -$5.67M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-03-31 | -$3.29M 10-Q · filed 2015-05-12 | -$5.08M derived: sum of 2 quarters · filed 2016-02-26 | -$5.75M derived: sum of 3 quarters · filed 2016-02-26 | |
| 2013-12-31 | -$1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | -$2.46M derived: sum of 2 quarters · filed 2016-02-26 | -$2.79M 10-K · filed 2016-02-26 | |
| 2013-09-30 | -$667.00K 10-Q · filed 2014-11-10 | -$998.00K 10-Q · filed 2014-11-10 | ||
| 2012-12-31 | -$349.00K 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |